

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method of treating cancer that expresses ErbB2 selected from the group consisting of ~~carcinoma, lymphoma, blastoma, medulloblastoma, retinoblastoma, sarcoma, liposarcoma,~~ synovial cell sarcoma, ~~neuroendocrine tumor,~~ carcinoid tumor, gastrinoma, islet cell cancer, ~~mesothelioma, schwannoma, and~~ acoustic neuroma, ~~meningioma, adenocarcinoma, melanoma, leukemia, lymphoid malignancy, squamous-cell cancer, epithelial-squamous-cell cancer, lung cancer, small-cell lung cancer, non-small-cell lung cancer, adenocarcinoma-of-the-lung, squamous carcinoma-of-the-lung, cancer-of-the-peritoneum, hepatocellular cancer, gastric or stomach cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophageal cancer, a tumor-of-the-biliary tract, and head-and-neck cancer,~~ comprising administering a therapeutically effective amount of an antibody which binds ErbB2 to a patient.
2. (Original) The method of claim 1 wherein the antibody blocks ligand activation of an ErbB receptor.
3. (Currently Amended) The method of claim 1 wherein the antibody blocks binding of monoclonal antibody 2C4 (ATCC HB-12697) to ErbB2.
4. (Currently Amended) The method of ~~claim 1~~ claim 3 wherein the antibody is monoclonal antibody 2C4 or humanized 2C4.
5. (Currently Amended) The method of claim 1 wherein the antibody is monoclonal antibody 4D5 (ATCC CRL 10463) or humanized 4D5.
6. (Original) The method of claim 1 wherein the cancer is

medulloblastoma.

7. (Withdrawn) The method of claim 1 wherein the cancer is retinoblastoma.
8. (Withdrawn) The method of claim 1 wherein the cancer is synovial cell sarcoma.
9. (Withdrawn) The method of claim 1 wherein the cancer is a carcinoid tumor.
10. (Withdrawn) The method of claim 1 wherein the cancer is gastrinoma.
11. (Withdrawn) The method of claim 1 wherein the cancer is islet cell cancer.
12. (Withdrawn) The method of claim 1 wherein the cancer is acoustic neuroma.
13. (New) A method of treating blastoma that expresses ErbB2 comprising administering a therapeutically effective amount of an antibody which binds ErbB2 to a patient.
14. (New) The method of claim 13 wherein the blastoma is medulloblastoma.
15. (New) The method of claim 13 wherein the antibody is monoclonal antibody 4D5 (ATCC CRL 10463) or humanized 4D5.
16. (New) The method of claim 15 wherein the antibody is a humanized 4D5 antibody comprising huMAb4D5-8 (HERCEPTIN®)
17. (New) The method of claim 13 wherein the antibody blocks binding of monoclonal antibody 2C4 (ATCC HB-12697) to ErbB2.
18. (New) The method of claim 17 wherein the antibody is monoclonal antibody 2C4 or humanized 2C4.
19. (New) A method of treating medulloblastoma that expresses ErbB2 comprising administering a therapeutically effective amount of a

humanized version of monoclonal antibody 2C4 (ATCC HB-12697) to a patient.